About Nuo Therapeutics
Nuo Therapeutics is a company based in Gaithersburg (United States) founded in 2001. Nuo Therapeutics has raised $69.12 million across 18 funding rounds from investors including MidCap Financial, Anson Group and Maryland Department of Commerce. The company has 9 employees as of December 31, 2024. Nuo Therapeutics has completed 2 acquisitions, including Aldagen and Angel Systems. Nuo Therapeutics offers products and services including Aurix. Nuo Therapeutics operates in a competitive market with competitors including Adocia, Imbed Biosciences, Cresilon, Ilya Pharma and QBiotics, among others.
- Headquarter Gaithersburg, United States
- Employees 9 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology Aerospace, Defense & Maritime
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nuo Therapeutics, Inc.
-
Annual Revenue
$1.37 M (USD)124.34as on Dec 31, 2024
-
Net Profit
-$2.32 M (USD)26.73as on Dec 31, 2024
-
EBITDA
-$2.36 M (USD)22.9as on Dec 31, 2024
-
Total Equity Funding
$69.12 M (USD)
in 18 rounds
-
Latest Funding Round
$791.42 K (USD), Post-IPO
Jul 30, 2025
-
Investors
MidCap Financial
& 3 more
-
Employee Count
9
as on Dec 31, 2024
-
Investments & Acquisitions
Aldagen
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nuo Therapeutics
Nuo Therapeutics is a publicly listed company on the OTC with ticker symbol AURX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nuo Therapeutics
Nuo Therapeutics offers a comprehensive portfolio of products and services, including Aurix.
Biodynamic hematogel using patient's platelets for wound healing.
Funding Insights of Nuo Therapeutics
Nuo Therapeutics has successfully raised a total of $69.12M across 18 strategic funding rounds. The most recent funding activity was a Post-IPO round of $791.42 thousand completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nuo Therapeutics
Nuo Therapeutics has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include MidCap Financial, Anson Group and Maryland Department of Commerce.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private debt funds are managed across multiple sectors.
|
Locked | Locked | Locked | |
|
Diversified operations are conducted across multiple industries by Anson Group.
|
Locked | Locked | Locked | |
|
Government agency focused on development of Maryland
|
Locked | Locked | Locked |
Investor details for Nuo Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nuo Therapeutics
Nuo Therapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aldagen and Angel Systems.
Investment portfolio details for Nuo Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Regenerative cell therapies for vascular disorders
|
Locked | Locked | 2001 | Locked | |
|
Provider of pest control services
|
Locked | Locked | 1988 | Locked |
Complete acquisition details for Nuo Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Nuo Therapeutics
Detailed financials for Nuo Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nuo Therapeutics Comparisons
Peer comparison for Nuo Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nuo Therapeutics
Nuo Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, Imbed Biosciences, Cresilon, Ilya Pharma and QBiotics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Nanotech-based wound care products are developed and provided.
|
|
| Locked | Locked | Locked |
Developer of hemostatic products for wound care
|
|
| Locked | Locked | Locked |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules from plant extracts are developed for medical applications.
|
|
| Locked | Locked | Locked |
Enzymatic therapies for tissue repair and regeneration are developed.
|
Detailed competitors of Nuo Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nuo Therapeutics
Complete news archive for Nuo Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuo Therapeutics
Nuo Therapeutics was founded in 2001 and raised its 1st funding round 9 years after it was founded.
Nuo Therapeutics is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
David Jorden is the current CEO of Nuo Therapeutics.
Nuo Therapeutics is a funded company, having raised a total of $69.12M across 18 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Nuo Therapeutics is 9.
Annual revenue of Nuo Therapeutics is $1.37M as on Dec 31, 2024.
Founded in 2001 and based in Gaithersburg, United States, regenerative products targeting wound care, inflammation, and angiogenesis are developed by the company. Operations center on autologous platelet and plasma therapies, with the proprietary Aurix systema biodynamic hematogelapproved by the FDA for managing wounds and ulcers of varying types and severities. Focus remains on advancing therapies within the biotechnology sector.
Nuo Therapeutics's top competitors include Imbed Biosciences, Adocia and Ilya Pharma.
Nuo Therapeutics offers Aurix.
Yes, Nuo Therapeutics is publicly traded on OTC under the ticker symbol AURX.
Nuo Therapeutics has made 2 acquisitions, including Aldagen, and Angel Systems.
Nuo Therapeutics has 4 investors. Key investors include MidCap Financial, Anson Group, Maryland Department of Commerce, and Aldagenholdings.
The ticker symbol of Nuo Therapeutics is AURX on OTC.